Reviva Pharmaceuticals Holdings (RVPH) risk factors
Item 1A of every Reviva Pharmaceuticals Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors72 risks2 dropped11 reworded
The company faces a Nasdaq minimum bid price deficiency notice, threatening delisting of its common stock. Insider ownership concentration decreased significantly from 34.16% to 12.7%.
Filed Mar 30, 2026 - FY2024 10-K risk factors74 risks
Reviva Pharmaceuticals faces substantial going concern doubt with an accumulated deficit of $164.3 million and zero product revenues. The business is heavily dependent on the clinical success and regulatory approval of its lead drug candidate, brilaroxazine. Operations are constrained by a tiny headcount of fourteen employees and a heavy reliance on future external financing.
Filed Apr 03, 2025